Piperazine, 1-(3-methyl-2-pyridinyl)- (9CI) → 2-{[4-(3-Methyl-2-pyridinyl)-1-piperazinyl]methyl}furo[3,2-b]pyridine

HRID 1828294

反应方程式

HRID 1828294 反应方程式
[CH3:1][C:2]1[C:3]([N:8]2[CH2:13][CH2:12][NH:11][CH2:10][CH2:9]2)=[N:4][CH:5]=[CH:6][CH:7]=1.C(O[BH-](O[C:24](=[O:26])[CH3:25])OC(=O)C)(=O)C.[Na+]>>[CH3:1][C:2]1[C:3]([N:8]2[CH2:9][CH2:10][N:11]([CH2:7][C:6]3[O:26][C:24]4[C:25](=[N:4][CH:3]=[CH:2][CH:1]=4)[CH:5]=3)[CH2:12][CH2:13]2)=[N:4][CH:5]=[CH:6][CH:7]=1

参与物

3

反应物 2

HCID 2760057Piperazine, 1-(3-methyl-2-pyridinyl)- (9CI)HCID 5049666三乙酰氧基硼氢化钠

产物 1

HCID 98614252-{[4-(3-Methyl-2-pyridinyl)-1-piperazinyl]methyl}furo[3,2-b]pyridine

实验过程

The product from Example 35B, 1-(3-methyl-2-pyridinyl)piperazine, and sodium triacetoxyborohydride were processed as described in Example 35C to provide the title compound. 1H NMR (CDCl3, 300 MHz) 62.68 (m, 4H), 3.29 (s, 3H), 3.58 (m, 4H), 3.79 (s, 2H), 6.41 (d, J=8.48 Hz, 1H), 6.49 (d, J=7.12 Hz, 1H), 6.85 (s, 1H), 7.18 dd, J=4.75, 8.14 Hz, 1H), 7.36 (dd, J=7.12, 8.14 Hz, 1H), 7.73 (dd, J=1.02, 8.14 Hz, 1H), 8.51 (dd, J=1.36, 4.75 Hz, 1H); MS (DCI/NH3) m/z 309.2 (M+H)+.

来源与证据

ORD记录
ord-0669a961823941a6a897f16dc1efa5ec
来源数据集
uspto-grants-2006_06
专利号
US07057042B2

关联笔记

加载中…